<SEC-DOCUMENT>0001144204-13-008663.txt : 20130214
<SEC-HEADER>0001144204-13-008663.hdr.sgml : 20130214
<ACCEPTANCE-DATETIME>20130214110037
ACCESSION NUMBER:		0001144204-13-008663
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130214
FILED AS OF DATE:		20130214
DATE AS OF CHANGE:		20130214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		13607752

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v335228_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED
STATES </B>&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Washington,
D.C.&nbsp;20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of&nbsp;the Securities Exchange Act of
1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of February 2013<BR>
Commission File No.:001-35773</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REDHILL BIOPHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>21 Ha'arba'a Street, Tel Aviv, 64739,
Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings 2">S</FONT>&nbsp;Form
40-F <FONT STYLE="font-family: Wingdings 2">&pound;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark if the Registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark if the Registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Attached hereto and incorporated by way of
reference herein is a press release issued by the Registrant and entitled &ldquo;RedHill Biopharma Announces Date of 2012 Financial
Results and Corporate Update Conference Call&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Signatures</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&#9;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Date: February 14, 2013</P></TD>
    <TD STYLE="width: 10%; text-align: left; direction: rtl; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: left; direction: rtl; unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-size: 10pt">REDHILL BIOPHARMA LTD.</FONT><BR>
<FONT STYLE="font-size: 10pt">(the &quot;Registrant&quot;)</FONT><BR>
<BR>
<FONT STYLE="font-size: 10pt">By: /s/ <I>Ori Shilo</I></FONT><BR>
<FONT STYLE="font-size: 10pt">&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;</FONT><BR>
<FONT STYLE="font-size: 10pt">Ori Shilo</FONT><BR>
<FONT STYLE="font-size: 10pt">Deputy Chief Executive Officer Finance and Operations</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v335228_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: Black 2pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 24pt; text-align: center"><FONT STYLE="font-size: 24pt">Press Release</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Date: February 14, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RedHill Biopharma Announces Date of
2012</U></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Financial Results and Corporate Update</U></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RedHill Biopharma Ltd. </B>(NASDAQ:
RDHL; TASE: RDHL), an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage,
patent-protected, new formulations and combinations of existing drugs, announced that it plans to release its FY 2012 results on
Tuesday, February 19<SUP>th</SUP>, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will host a conference call
and an audio webcast at 09:00am EST on Wednesday, February 20<SUP>th</SUP>, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To participate in the conference call please dial 1-866-966-9439
(domestic U.S., toll free) or +1-631-510-7498 (International) and use access code: 11015754 #.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The conference call will be broadcasted
simultaneously and archived on the Company's website, http://ir.redhillbio.com/. To participate, please access the Company's website
at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. The webcast replay
will be available on RedHill&rsquo;s website for 30 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About RedHill Biopharma Ltd.:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RedHill Biopharma is an emerging Israeli
biopharmaceutical company focused primarily on the development of late clinical-stage, patent protected, new formulations and combinations
of existing drugs. The Company's current product pipeline includes a once-daily formulation of a leading congestive heart failure
and high blood pressure drug, a once-daily formulation of a leading chemotherapy and radiotherapy-induced nausea and vomiting prevention
drug, an oral thin film formulation of a leading drug for the treatment of acute migraine, a combination therapy for the treatment
of Crohn's disease as well as Multiple Sclerosis (MS) disease, a combination therapy for the treatment of Helicobacter pylori bacteria
causing ulcers, and an encapsulated formulation for bowel preparation ahead of certain gastro procedures. For more information
please visit:<I> www.redhillbio.com. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IR contact</B> <B>(US)</B>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lauren Glaser</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Trout Group</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1-646-378-2972</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">lglaser@troutgroup.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD>
    <TD STYLE="width: 54%; padding: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company contact:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adi Frish</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Senior VP Business Development &amp; Licensing</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RedHill Biopharma</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+972-54-6543-112</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">adi@redhillbio.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">***</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!:`)8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBFSW"6L#RRNL<<2EG=B%50!DDD]`!0V,S_%OC/2/`.ARZGKNJZ=HVFP8$EU?
M7*6T$>>F7<A1GZU\-_MW_P#!?'X9_LS6<VD>`FM_B5XN=/E:UEQI%F3WDN%_
MUI'79%GT+H:\B_X*C?'74?VH?%Z:)I\DJ>#]`D;[+$,C[9-@JUPP]<$A0?NJ
M3T+,*^`OB!\"!*)`T&[\*^`S7B^<:LJ.&7NK3F_R6Q_17AWX79155+&9_*4F
M]?9I\J\E)KWGYI./:^Y^A7AS_@Y^\#OX0T%]6^''B5=>GF6/6(K6[A-I:Q\;
MI8';YI">2(V5,8P7_B/W?^S;^W!\+?VM/"9UCP-XPTW5((Y!#-!+NM;JWD*A
MMK12A7Z-U`*D@@$X-?S1>+/@]=Z/([0!F4?PG_&N0GMYK"4I(KQNIZ'BHP?%
M5>]YVFON?X?Y'ZEF_@!POF5&^4U)8>=V[W<U9O9QDT]-E:2\^8_KC!R`<YS1
M7X&_L??\%_OB9^RO\$-/\#WFA:/XVM=&)CTZ\U*>9+FVM\#;`2I^=4.=I/(!
M"]`H'ZO_`+`O_!3GX>_MQ_#GP]);:UHVC^/=1AD%[X7>]4WL,T0S*T2$AI(B
MHWJP'W3S@JP'UN"SG#8EJ,7:5MG^5^I_./&7A)Q!P[&>)Q%/GH*32G%IZ:M2
ME%-RBFEK=63TOM?Z3HHHKU3\P"BBB@`HHHH`****`"BBB@`HKX5_X+!_&'XL
M^&/C?^S9\/OA7\1[GX9W'Q5\1WVD:CJD.E6VHE42*!HV\N=2#M+/P"N=W)XI
MO_#O']KW_H^?6/\`PVNE?_%T7`^[*\>_:C\77.H>'Y_#]@S!;@8NW7^(?\\_
MIZ^O3IN!^7/@S^U9\?/V+OVYO`WP*_:%\0Z!\2_#WQ:MKE?!WCO3=+72[D7M
MNF][6ZMT_=@E2H!7.#)&=S98)]G>*OALNI!V52[,<^IS7%CZ<ZE%PAUW/1RR
MM3I5XU:FMM5ZGP5XV^#6XR$QDD^U>0>-_@IG?^ZS^%?H1XQ^$3*K&2W9-W0E
M2`:\K\9?!WS"X$.2?:OSS&Y,U?0_8,IXL:M[Q^<_CKX'A@_[K.?:O%?'_P`!
MUF#AH<X]N17Z6^,O@7)YGSVKA2P!RA`KX4^"VH:_\2O@_P#&;5]4O6O+OPCX
MFUW3M/D,2*;:&VCW1)@``[3W.2>^:\1Y;52E.+M:WXGZ;E?B#]7J0@V[M-Z?
MW5?_`(8^7/%/PDO-%=VA#2*O\)ZU6^%GQ2\2_`'XE:3XJ\,:C<Z'XCT&<7%E
M=QJI>%\$'A@58$$@@@@@D$$$U]!?LY>%=1^+_P"R_P"#O$VKR&^U/6+$SW%P
M45#*WF.N<*`!P!T%<_\`$7X$*8)F,&2BLP.,$8%$J]3#UG2J;Q=KKNF?KN1\
M;X7,\'&6(C>%2*;32VDMI+5/1V:V/HGPC_P<G?&S0/"/A[3[_1_".M7^F76_
M4M2N+5HYM7@SQ$5C98XFP3ET7G"\##;O<?'?_!T5IZ?V0/#/PJNY-QB?5#J>
MK*NP<>9'"(T.[N%D;'8F/M7XX>#_``YKWB[X.)JUK)Y^H7(G2)R`N'5V5>V.
MPJAXIO;_`$*VT2-W:*YGO88+GY1\X*G</Q([5]53S#'1J2H1K)R3<>[]WKJM
MGWZGP];A7@+'8*GG+RUJFZ<:ONWBG[622@U&:7-%M/E3M&+]UVT/Z$/#W_!Q
M?^S[KGB30-.E_P"$QT^+5PGVN^N--3[-I#,N=LNV0NV&X)C1AW&17I?[6?\`
MP6+^#'[(USX0CU+5KCQ2/%\/VZ%O#IAO1;69!"7+G>HV.P(4`DG:YQ\O/\T\
MNJ7"_$*&R$A^RO8-,8\#!<2``YZ]*V2Q/4DUT3XAQD()22;DDT^W]6//P?@-
MPICL3*>'E5C"C.=.<7)/GDDFFI)727,NFMK-+5O]H?A?_P`'+OA?Q3^TU+I/
MB#PE/H'PPO"+>RU<NTVHVKY_U]Q&N5,3=TCRR8SF3I7Z3>`/BWX5^*UM+-X8
M\2Z%XBC@CBEE.FW\5UY2RJ6C+;&.T,H)&<9`.*_DXKUK]CC]M/QS^PY\78?&
M'@F^C2Y,1MKRQN@TEGJ4!ZQ3(""0#A@005(!!ZY,%Q+5A*V(]Y-[]5_F5QG]
M'C*\50]KD$O8U81LHMN49M6LVVVXMJZ;5TW9V6M_ZCJ*^2/^"4__``5,T[_@
MHYX,UR*]TFU\->,_#+HUYIT-P98KFW<86XBW`,%WAE9?FVG9ECO%?6]?9X?$
M4ZU-5:3NF?R#GN1XW)\=4R[,8<E6&ZT>ZNFFKIIIIIH****V/(/S>_X+G_&?
MP[^SQ^U=^QMXW\77LFG>&_#?C'4KS4+F.VEN6AB$-MEA'&K.W7HJD^U=]_Q$
M;?LC?]%&U<_]RCJ__P`C5D_\%9HUF_X*!?L-HZJZMXZU$%6&0?W%M7W?_8=E
M_P`^=K_WZ7_"D!^;/PR^+J?\%J_^"AGPM^(O@6PGL_@?^SG<7M__`&SJ#1P7
MOB+6+F)8XXHK;<98X8]BOOD5=VUQC)6NF^.Q\:_\%2/^"@WC3X(Z3XV\4?#_
M`.!_P4L[(^-+KPU=M8ZIXKU:[3S8[`7*_-';QQ`[PO)8,#G<A2I^T-X"T[]E
MS_@OA^SUXH\(V4.A1_'+1=<T'Q5!9*((-6DL[;SX9I47`:7<T7S8R?*7WSY3
M\%/V#_#G[0?_``59_:T\)>+?B#\7/!'B6+6['Q3IEKX4\52Z-%JVFW<`/GE$
M4^;Y3E(RW\.\"@#J_P!L#]BC4_\`@C[\.G^/?P'\7>/[KPYX)G@N?'7@+Q#K
M]QK.E^(M',BI<2P_:&9X+J)6\P.IQA3TQANC_P""AWQ8\4_'CXY?!G]GSX*^
M)KGPG??&;2IO%VO>+;6,->:'X:B4'=;9^[/.S;%;J,8!&21D_MO_`/!*_P"!
M'[+W[+GBWQG\4OC+^U!J'@C3[98=1L&^($MVVI"9UB6W6"10LK.S@;"<'DG@
M&I]*TG2/V;/^"U'[.$LD6J:9X2\;_`MO`WAEM:PMU%=6<L=PMK,W3[08-@8#
MJ[8&<BLZE*,MT:PKSA\+,KQA_P`$1M/^$^D/K?P=^(/Q3\,_$O3$^T6.IZMX
MIN=7LM8G7YA#?VTQ,<D4I&UMH4KNR.F*^8/^":6FWGQ-_8%_:)\0ZIIPTO5+
MOQ5XHN+RR!W"RG-FK21`GJ%<LH^E?N-XE&FZ)I-UJFI3V]E8Z;$UU<W,SB..
M")`6=V8\!54$DGH!7Y-?\$C+VP^,W_!-3]K#Q?IR8TW7/&WC/4K+C'[F6Q66
M,X[95U/XUYF*P#G!Q>MVOP/9P6:^RJ1DM+)^FJ/D/]B/]J";P?\`L7_#W1A\
M%OC/XC%AIAC&JZ3H0GT^]S-(V^*3<-R\XSCJ#6OXT_:9FU&SN0?@;\;X-T;C
M=+X?"A>#R?GZ5]W_`/!&OX<-K7_!)7X'70#?OM!D/M_Q]SUZ9\2OA(ZZ-J!:
M-CBVF.1_N-7S&98"C[:<W2O=OJ^Y][D6?XNG0A"&(Y4DE;EB]D?B5\+/"$\7
M_!,K5?$5NTL%S9V>IRQS1L5>-EG?!!'0BL#XV_#EX_`/PMO)`SRZSJ.G(\C<
MLYD@+$D]R3S7T%\$/`_VO_@@YXMU?9DPZ7KS;O\`=NG%0?M+?#O['\"_V:)M
MG_(2\0:!'TZ[[3-85:#CBI376K-_^2GT66\1SCET:',[+#T8VOII43/E;Q?X
M%N=`^.<-BBO*_P#8TDP'?;YP%221M$Y5P58=01@BOHCXG?"O;^WO8Z7Y?W_!
M<]QC'I=`52^('P$60N?)(8=&`P17AXK%.*I*:^POS9_17`O%-&4L8JK^*O-W
M]8P_R/`Z*Z+Q)\-K_0I&(1I4'M\PKGF4HQ5@0PZ@\$41J1DKQ9^L4J].K'FI
MNZ/8OV"OVNM5_8C_`&G_``WX]T[S9K:RE^SZK:(<?;[&0@30\\9*_,N>`Z(>
MU?TW?#_Q[I'Q3\#:1XDT&^AU+1==M([ZRNHCE)XI%#*P_`].H/!YK^2ZOT;_
M`."&O_!5P_LT>+K?X4^/]0(^'^OW.-,OIW^7P]=N>Y/W;>1C\W9&._@%S7TN
M09HJ$_857[LOP?\`DS\"\=?#:IG>$CG.71OB*":E%;SAOIWE#5I;M-K5J*/W
M-HH5MR@@Y!Y!'0T5]Z?PZ?.?[;/P1^&?CGXT?!3QW\0?B!:>";[X6:U<ZQH<
M%UJ%K:0ZO*R1+(C^=\S*H5#\A!&_GJ*[[_AM;X._]%4^'G_A0VG_`,<J/Q];
MQW'[77PZ$D:28\.:_C<H./WVE>M>EG2[8@@V\!S_`-,Q0!X7\</V4O"'[:/Q
M/^#/Q1T_Q?<I=_"/6)]7T6\T2XM[JTU)9E2.>"1L,&C98PI*$$9/-8/[7W_!
M.[PE^VGXS\._$?PYXRU_X>_%#P@LUCI/C3PI=)]H6(2,LEI<*<I<1+)Y@,;8
M*L77(!93UL_A#3_@]^V%X:/ABRATNW^(.F:DVOV-H@BMKF6T^SO#?&-<*)E\
MUHFD`RXEC#$[$QVWP='A7PA\+KB70=35_#MIJ&JW4]W<R[4AE-]<R7FYF"A5
M2<S#)X`7J1R0#YD\.?\`!(K5/B'\4?#7B;X^_''QO\=[?P9>+J6C:!?:?:Z/
MHD5VA_=W$]K;C;.Z=MQ`Z@@@E3[?^VS^PYX'_;T^$T7A;QI%J-M+IMVFIZ+K
M6EW'V75=`O8_N75K,`=CCT(*D=1P"$_X;H\$36AU&WM/&]]X;"F3_A(+3PGJ
M,^DF,9S*LZPD/%Q_K%!3'.['->@ZA\6O#6F?#4^,GUJPE\+"U6]&IV\GVBWD
M@;&V16CSN4Y&"N<YH`^1C_P20\:_%"S@\._&+]IWXH_%'X<0LOVCPN;*TT=-
M9C4@B"_N;<>=<Q'`W*67?W->L_L__P#!.KPE^SE\&_BUX'T'4M371OBUK>K:
MU<IY<,8T?^T(%@:WME1`JQ1(H"!@2.Y(KM?&7[6GA3PIXMO]!M(O$GBK6=)9
M4U&U\.:)=:L=-9AN"SO"C)&Y4@^6S!\$';@@UTWPL^,GAWXSZ/<WOA[4#=BP
MG-I>V\T$EK=Z?.`"8IX)566)\$':Z@D$$9!!(!Y]^Q1^RCX5_97_`&3O!?PT
M\+ZY=>)-`\&6LNG6FI3RQ237&)Y6?>8@$W*[.I``P5P>0:[C7?@KI6OV-Q!*
M]PJW,3Q,5VY`92,CCKS7CG[/'[17AGX0_!/1M&O7U74_$-_J.N7=OHVBZ9/J
M>H20#6+Q3,88$8I%NR/,?:A((!)&*]<^%7[0OAGXOZK?:7ITVHV.O:7$D]YH
M^K:?/INHVT;DA)3!.JLT;$$"10R$@C=D$5E.C"?Q(VIXBI#X)6/FKP+_`,$4
M?`'@/]@K6/@#!XF\4W&@ZS:W]K)JLOV?[=&+N4R.5PFS*EL#*].N:D^)G_!%
MCX?_`!.\`_"WP_=>)/%%M!\*]2T[4K*6'R/,OFLX?*19LQD;6')VX.>F*^D/
MBC^T/X:^$NLVNDW\NIZEK]_`US;:/H^FSZGJ$L*MM,ODP(S)&#D>8^U,@C.>
M*B^&'[2'AKXJ>(Y]#MAK6C^(K>V^V-I&N:5<:9>M!NV^<B3(OFQAB`6C+!2R
M@D$C.<L'0;NX];_-F\<QQ,5RQF[62^2U2^\^</$7_!$[X>>(_P!H^V^),OB/
MQ5'J%KH,F@BR0V_V9HWF\TR',>[>#QUQBK^K_P#!&GX>:SN\S7?$R[O[I@_^
M-U[YXO\`VH_!'@II(+G5Y+K45U&72(M-L+*>\U"ZNXHTDDBBMXD:238DD99E
M4HH==S#-5KW]K3P7I.A&[OKO4[*^6:"U_L>72[@ZLUS/#YT5LMJJ&5YC%\Y1
M5)502V`"1QU<DP-2W/33LK+?8]7#<69OA[^PKRC=W>V_?8^8=8_X('_"_6<^
M9XE\8)G^ZUM_\:KDM;_X-KOA!KC%G\7^/(W/\4;V@/\`Z)K[0\!_M2^$_'%[
MJ%E-)JWAC4]+LGU.YL?$FFS:/.EFAP]T!.JAX5/#.A(0D;MN1G"M?VZ/`D\<
M-]*GBVR\-W)01>)+SPU?6VBN'("O]J>((L1)&)6Q&<YW8(-0N'\O3NJ2_'_,
M]JAXG<4T?X6-FON_R/C7_B&&^$7_`$/OQ&_[[L__`(Q2C_@V'^$0(/\`PGWQ
M'R/]NS_^,5^BWC;QUH_PW\)7VO:]J5II.CZ;'YMS=W,@2*)<@#)/4DD``<DD
M``D@5YK)^VYX.T_%QJMAXYT#1&90-;U?PIJ%CIBAB`KO-)$!$AR/GEV*,\D5
MI_8N!_Y]K\3M_P"(O\8_]!\_NC_\B='^S1\$9OV<_@UH_@Q_%&N^+K?0H_L]
MI?ZP8VNU@'^KB9HU4,$'RJ2,[0!DXHKNT<2(&4A@PR".0117I0BHQ48[(_/L
M7BJF)K3Q%9WE-MMV2NWJW967W(\1^/\`HOB37OVG_AO#X7\06'AV_70=>:2X
MN]*_M%'C\W2\H$\V+:<X.[<>F,<UJO\`#3XQE&"_%;PN&(X)\#D@'U_X_J3X
MI>(M/\-_M9?#F;4K^RT^)O#NOJKW,Z0JQ\[2^`6(R?85W1^+GA102?$_AX`<
MD_VC#Q_X]5'.>-?!31?$'P>_:"-O\3;F/Q5XK\:6LEIHWC"V4P6DT4`,S:8M
MGR+)M@:8!7D\\1.6DW1JM<EX6TZ+XE>#?AS\/+Y?.T/Q+XS\4:GK5N<%+^TL
M-5O91;.#]Z-[F2U+J>'1&4Y5B*]"\0_$+2_VCOCAX(TKPA=PZ]I7@?59-?US
M6;&02V-JZV=Q;P6:S+E))W:YWLB$E$B;?M+H&X7PM:W?A;X/^#_B)8V5WJB^
M`O&7B:35+6TC::XETRYU34(+EHXU!:1XCY,^Q0698&506*@I@?52J$4*``%&
M`!P!7QW^T[HUS\*OA7^T=X+\-/!96M_X8A\6Z%;[,P:9>WDES#.JKT$;7-LD
MY4<;YY3WKZATSXQ^$M8\!+XJMO$^@3>&FA^T?VJ+^+[&L>,EC+NV@`=<D8[U
M\P_'XW_QI_9K^/7Q$L#)IMCXG\.1:!X2N+N!HVEM+;SF2_*'YA'+<W4K)D`M
M%%&_1P*8'T[\(OA?IWP;^'VG^']-4M':*7GN'YFOKAV+S7,K=6EED9G9CR68
MFN&^)>D)X$_:H^'GB:P5+>7QB;KPIK(4$?;D2TGOK1W'0M"]M,JD\A;J0=#Q
MT?P6^/&E?%C1YH'G@T_Q1HQ^S:[HLT@2[TJY48=60G/ED@LD@^61"K*2#FN0
MD\66O[0/[3OA^'P_<IJ7AWX7-=7VJZC`1):/JLUNUK#9QR#AY(X9KF24+GRR
MT(/+8`!F?\$Z_AM;>#?@SK.LD_:=7\4^*=<N[NZ<`R&)-5NX[:`'J(XHE"JO
M0%G;J[$]'^T)90Z7\9/@UKD,835!XEN-&,XX9K2XTR]DEA/JADMK=\'C="A[
M4[]B-@_[.]B0<C^V-:Z?]A>\IW[2K`>.?@T">OCI0/?_`(E&J4`8R_$[X=_L
MV?%+QD_B'QC97?B_Q?J$>H7-K!:R7-_9VJ0)%;6[10"201HJ.RE@H9I9&`RQ
M)YGXA?M!Z)\5/CS\%QX=T;Q7.8/$]Q'+K=WH%WIMG;1/I-_O@\RZCC:0RLL9
MVQAA^[#,1M%='^POK>CV_P`,]7TV:>SA\<66NZC)XMMY&5+X7S7<K&68?>*O
M$8S$Y^4P^5M.T#')_'S]I'2?%G[2GPET30[_`$V]T'PYXO=_$NM?:%%E87+:
M5J$=M8K-G8UP[N69`<HJJ&P9$#`'1_LD_#BUL_C?\<O%DY%SJ>H>,7TZU=U!
M-C:1V-DQAC/\(><R2-C[Q*9SL7#?@O\`#Z&[_;O^-'BFZ(N)[.'1M-T]&&19
M!K)9+AU]&E_<*QZX@4=*Z3]EMP^N?%@@AO\`BN[KIS_RYV5)\%&!_:7^-(SD
MB^TC/M_Q+8J`.=_;F^%VG?$_5_@[;:@&\H>.[>*X50,7EJUG=O-:29^]!*8H
M]Z'A@@!S7N6N:):>)M$O--U"WBN['4('MKF"50R31NI5D8'J"I((]Z\Q_:@8
M+XF^$63C/CNW`]_]`OZ]8H`^:/A]/H%Q^RG\"?%OCSQ3I^D:'X2L[+4)(]29
M1'J=XMDT-KEF;+2(S&55`9FD1"!E0:[#6?VS?AYXKT*\L;&T\6>,1>V[Q'3]
M-\):E<B^5E(,>YH!"`P)&7=5P>2!7D7[-NKZ3H&N?L_7GBJ6TM]+F^'K6WAJ
MYO2JVR:JSP&9$9OE6Y>V`"=&9%G"\;Q7T)\=OV@](^#7A\1++%JGBO50;?0=
M!MG#WVL71'R1I&.0F<%Y"`D:!F8A030!F_L/ZC<ZM^QU\+[B[$J7,GAC3_,2
M5P\D9%N@V,PR&9<8)!.2,Y-%9_\`P3^U==4_8O\`AFC7NGWM_9^';*WOS9S"
M2.*Y6%1*G'(PX88.",<@&B@#T?QK\,O#?Q*AMX_$?A_1-?2T9F@74K"*[6$L
M`"5$BG:2`,XZXKGU_9<^&2,&'PZ\"!E.01H%H"/_`"'7=T4`0:7I=MHFGQ6E
ME;06EK`NV*&",1QQCT"C@#Z4ZRL(--@\JWAB@BW,^R-`B[F8LQP.Y8DD]R2:
MEHH`X:]_9A^&^I>*7URX\`>#)]8DE^T/>2:+;M.\N<^86*9+YYW'GWK-_;&\
M-ZCXO_9B\9Z9I5E<ZCJ-YIYC@MK="\LS;E.%`ZFO2Z*`.3^(/P'\$_%B^@NO
M%'A'PUXANK9/+BGU'38;F6-,YVAG4D+GG&<5O^'?#>G>$-$MM,TFPLM+TZS3
MR[>TM(%@@@7.=JHH"J,]@*NT4`16.GP:7;"&V@BMX0S,$B0(H+,68X'&222?
M4DFBYL(+V2!YH8IGMI/-A+H&,3[2NY<]#M9AD<X)'>I:*`.2\?\`P"\#?%;4
M8KSQ/X.\,>(+R%!&EQJ&F0W$RH#G8'=2VW)^[G%:'_"KO#/_``A2>&O^$=T+
M_A'8U"KI7V"+[$H#;@!#MV`!N>G7FMVB@"&RTVWTT2BW@A@\Y_,D\M`F]L`;
MCCJ<`#)[`40:?!:W4\\<$,<]T09I%0!Y2!@%B.3@<#/05-10!%=:?!?-"T\$
M4S6T@EB+H&,3@$;EST;!(R.<$U+110!DZYX!T+Q/X6;0M3T72=1T5U5&T^YL
MXYK4JIR%\I@5P"!@8XK*^'WP)\%?":[GN?#'A+PWX?N;E=DLVGZ;#;2RKG.U
MF102N><$XKJZ*`,_0/".E>%'O&TO3-/TUM1G:ZNS:VR0FZF;[TC[0-SG`RQR
(3BBM"B@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
